The objective of this mentored research career development proposal is to investigate the role of the anaplastic lymphoma kinase (ALK) receptor in central nervous system development (CNS), neural stem cell (NSC) biology, response to hypoxic injury and glioblastoma (GBM). The rationale for this study is based on the high expression levels of ALK and its ligands Pleiotrophin (PTN) and Midkine (MK) during murine CNS development. The PTN-ALK signaling axis also provides neuroprotective effects after ischemic injury in the adult CNS and is reactivated in adult GBMs;however, an opportunity remains to define the function and mechanisms of action for ALK during these normal and diseased states. To determine how ALK signaling contributes to or regulates NSC biology, previously generated human and murine fetal NSC lines will be utilized to test how gain- or loss-of ALK expression alters NSC proliferation, apoptosis or differentiation. Additionally the intracellular signaling cascades and transcriptional networks activated in the presence or absence of ALK ligands (pleiotrophin and midkine) will be mapped in normal NSCs. Preliminary data suggests that ALK expression in GBM defines a distinct patient population with sensitivity to the ALK inhibitor crizotinib;therefore, a research study was designed to test whether ALK is a prognostic biomarker for GBM patients and determine if novel ALK fusions or mutations are involved in the pathogenesis of GBM. The functional effects of ALK fusions or mutations will be determined using scientifically relevant primary GBM cell lines. The Dana- Farber Cancer Institute Brain Tumor Biorepository and Living Tissue Banks provide unique access to a large cohort of clinically annotated GBM tissues and primary cell lines that will be used to conduct the proposed experiments. These research studies encompass a wide array of disciplines including neurodevelopment, ischemic brain injury, glioma biology, next generation sequencing, and clinic pathologic analyses, which together will delineate the mechanisms of action for the PTN-ALK signaling axis during normal CNS development and gliomagenesis.
The specific aims are:
Aim One : To characterize ALK rearrangements and evaluate ALK as a prognostic biomarker for GBM.
Aim Two : To determine intracellular signaling pathways and transcriptional networks activated by wild-type or mutant ALK (p.P399S, p.H1030P, or p.K1612N) in primary GBM cell lines and normal neural stem cells.
Aim Three : To test whether disruption of the Pleiotrophin-ALK signaling axis through in vivo loss of ALK alters neural stem cell biology or response to hypoxic brain injury.
ALK is a receptor tyrosine kinase highly expressed in the developing brain with retained expression throughout adulthood and is aberrantly activated in 10% of glioblastomas;however the precise function and mechanisms of action for ALK in the central nervous system and gliomagenesis remain largely unexplored. This proposal will deliver a comprehensive analysis of ALK signaling in neural stem cell biology, determine the relevance of the Pleiotrophin-ALK axis in response to ischemic brain injury, and demonstrate the scientific and clinical relevance of ALK as a biomarker and therapeutic target for glioblastoma patients.
|Miller, Michael B; Bi, Wenya Linda; Ramkissoon, Lori A et al. (2016) MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget 7:37054-37063|
|Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6|
|Bandopadhayay, Pratiti; Ramkissoon, Lori A; Jain, Payal et al. (2016) MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 48:273-82|
|Reardon, David A; Gokhale, Prafulla C; Klein, Sarah R et al. (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124-35|
|Kang, Yun Jee; Bi, Wenya Linda; Dubuc, Adrian M et al. (2016) Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurg 85:96-105|
|Wu, Winona W; Bi, Wenya Linda; Kang, Yun Jee et al. (2016) Adult Atypical Teratoid/Rhabdoid Tumors. World Neurosurg 85:197-204|
|Abedalthagafi, Malak; Bi, Wenya Linda; Aizer, Ayal A et al. (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18:649-55|
|Diamandis, Phedias; Ferrer-Luna, Ruben; Huang, Raymond Y et al. (2016) Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol 11:13|
|Shankar, Ganesh M; Francis, Joshua M; Rinne, Mikael L et al. (2015) Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol 1:662-7|
|Lee, Eudocia Q; Kaley, Thomas J; Duda, Dan G et al. (2015) A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res 21:3610-8|
Showing the most recent 10 out of 20 publications